Which domestic manufacturers are producing ivonib drugs?

Currently in the Chinese market, Ivosidenib/Ivosidenib (Ivosidenib) mainly exists in the form of original drugs, and domestic generic drugs have not yet been approved for marketing. Ivonib is a targeted therapy drug targeting IDH1 mutations. It is suitable for patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and cholangiocarcinoma. Its unique mechanism of action makes it demonstrate important clinical value in the field of hematological tumors.

Avosidenib sold in the domestic market is mainly the original version, with the trade name "Tibsovo", produced by PATHEON INC. in Canada. The specification of this drug is usually 0.25 grams per tablet, packed in a box of 60 tablets, and the price is relatively high, about 70,000 yuan. Although its efficacy has been widely confirmed by international clinical trials, its high price and the fact that it has not yet been included in the domestic medical insurance list limits its accessibility to some patients. In contrast, the research and development of domestic generic drugs is still in its early stages and has not yet entered the market. China's medical regulatory authorities are strict in reviewing anti-tumor drugs, and the clinical trials and quality control of domestic generic drugs must meet high standards to ensure that the efficacy and safety are consistent with the original drugs.

It is expected that as relevant companies accelerate research and development progress, domestic generic drugs of ivonib will be launched in the next few years, thereby promoting the affordability and popularity of the drug. Currently, if patients need to use ivonib, they mainly rely on imported original drugs. Doctors and medical institutions need to make reasonable treatment plans based on the patient's specific condition and economic status.

In general, although there is a temporary lack of domestically produced ivonib in the country, the market has strong demand for this type of targeted drugs. With policy support and technological advancement, the development and launch of the domestic version is just around the corner, which will bring new hope for treatment to more patients.

Reference: https://www.tibsovo.com/